Abcb5(+) stem cells for treating ocular disease
US-2015374756-A1 · Dec 31, 2015 · US
US2021207088A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2021207088-A1 |
| Application number | US-201917269278-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 30, 2019 |
| Priority date | Aug 31, 2018 |
| Publication date | Jul 8, 2021 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure provides a composition and method for preserving ocular cells. More specifically, the present disclosure provides a composition for preserving ocular cells, or culturing the cells after preservation, comprising albumin and dimethyl sulfoxide, and a cell formulation comprising the ocular cells, albumin, and dimethyl sulfoxide, and a treatment/prevention method using the same. The present disclosure also provides a method of preserving corneal endothelial cells, comprising suspending ocular cells in the composition to provide a suspension and freezing the suspension. In some embodiments, ocular cells are corneal cells (e.g., corneal endothelial cells).
Opening claim text (preview).
1 .- 30 . (canceled) 31 . A method for preserving ocular cells, comprising: suspending the ocular cells in a composition comprising albumin and dimethyl sulfoxide to provide a suspension; and freezing the suspension. 32 . The method of claim 31 , wherein the ocular cells are suspended in the suspension in a concentration of about 1×10 3 to about 1×10 8 cells/mL. 33 . The method of claim 31 , wherein the freezing the suspension comprises freezing without pre-freezing. 34 . The method of claim 33 , wherein the freezing without pre-freezing comprises freezing rapidly at about −80° C. 35 .- 70 . (canceled) 71 . The method of claim 31 , wherein the ocular cells comprise corneal cells. 72 . The method of claim 31 , wherein the ocular cells comprise corneal endothelial cells. 73 . The method of claim 31 , wherein the composition further comprises a saccharide. 74 . The method of claim 31 , wherein the composition further comprises a phosphate ion. 75 . The method of claim 31 , wherein the composition further comprises a metal ion. 76 . The method of claim 75 , wherein the metal ion is selected from the group consisting of a calcium ion, a magnesium ion, an iron ion, a zinc ion, a copper ion, an aluminum ion, and any combination thereof. 77 . The method of claim 31 , wherein the composition further comprises (i) a calcium ion and magnesium or (ii) calcium, magnesium, and copper. 78 . The method of claim 31 , wherein the albumin has a concentration of about 0.01 to about 25% (w/w) in the composition. 79 . The method of claim 31 , wherein the dimethyl sulfoxide has a concentration of about 0.1 to about 50% (w/w) in the composition. 80 . The method of claim 75 , wherein the metal ion has a concentration of about 0.0000001 to 5% (w/w) in the composition. 81 . The method of claim 31 , wherein the composition further comprises (i) about 0.1% (w/w) calcium and magnesium in the composition or (ii) about 0.1 to about 5% (w/w) calcium, magnesium, and copper in the composition. 82 . The method of claim 73 , wherein the saccharide has a concentration of about 0.1 to about 10% (w/w) in the composition. 83 . The method of claim 31 , wherein the composition is Bambanker®. 84 . The method of claim 31 , wherein the ocular cells comprise corneal endothelial cells, and the method further comprises: preserving the suspension, and administering the preserved suspension to a subject. 85 . The method of claim 84 , wherein the preserving comprises cryopreserving the suspension. 86 . The method of claim 84 , wherein the corneal endothelial cells are not cultured prior to administering to the subject.
Physiologically active agents, e.g. antioxidants or nutrients · CPC title
Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title
Sugars · CPC title
Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062) · CPC title
Calcium; Ca chelators; Calcitonin · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.